



# HHS Public Access

Author manuscript

*S Afr Med J.* Author manuscript; available in PMC 2021 December 28.

Published in final edited form as:

*S Afr Med J.* ; 111(9): 822–823.

## Stillbirth rate by maternal HIV serostatus and antiretroviral use in pregnancy in South Africa: An audit

**S Maswime,**

Global Surgery Division, Department of Surgery, Faculty of Health Sciences, University of Cape Town, South Africa

**C Pule,**

Global Surgery Division, Department of Surgery, Faculty of Health Sciences, University of Cape Town, South Africa

**L M Bebell,**

Massachusetts General Hospital Center for Global Health, USA; Harvard Medical School, USA

**B Hedt-Gauthier,**

Massachusetts General Hospital Center for Global Health, USA; Harvard Medical School, USA

**N Chandiwana,**

Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa

**J E Haberer,**

Massachusetts General Hospital Center for Global Health, USA; Harvard Medical School, USA

**R Pattinson**

South African Medical Research Council/University of Pretoria Maternal and Infant Health Care Strategies Extramural Unit, South Africa

---

The global perinatal mortality burden is high, with over 2.6 million stillbirths annually.<sup>[1]</sup> The plurality (41%) of stillbirths occur in sub-Saharan Africa, which also has the highest HIV burden (20% prevalence) in the world.<sup>[1,2]</sup> The extent to which these two phenomena are related has not been fully characterised.

In 2003, South Africa (SA) introduced a national HIV prevention of mother-to-child transmission (PMTCT) programme,<sup>[2]</sup> and by 2017 over 90% of all pregnant SA women living with HIV (WLWH) were receiving antiretroviral therapy (ART).<sup>[3]</sup> As a result, the proportion of HIV-exposed children who acquired HIV perinatally in SA declined from 18.0% in 2010 to 2.7% by 2017.<sup>[4,5]</sup> Despite this impressive accomplishment, *in utero* and perinatal HIV transmission still occurs too frequently, and has been linked to a variety of

---

This open-access article is distributed under Creative Commons licence CC-BY-NC 4.0. <http://creativecommons.org/licenses/by-nc/4.0/>

salome.maswime@uct.ac.za .

**Author contributions.** SM: conception of idea, and draft of manuscript and all revisions. LB and JH: conception and reviewing of all the revisions. BH: data analysis and reviewing of manuscript. RP: Provision of data, conception, data analysis and contribution to manuscript. NC: revision of manuscript.

poor fetal and neonatal outcomes, including stillbirth, preterm delivery, intrauterine growth restriction, low birthweight and mortality.<sup>[6]</sup> Although there are tremendous benefits to ART, there is also concern that combination ART (cART; use of three antiretroviral medications simultaneously) may alter fetal and placental development. Some studies suggest cART is associated with a higher risk of stillbirth, preterm delivery and low birthweight compared with prophylactic (i.e. single or dual drug) ART for PMTCT.<sup>[6-8]</sup>

To address the gap in knowledge of the effects of ART on the developing fetus, we analysed outcome data for all deliveries captured in the SA Perinatal Problem Identification Programme (PIIP) database, a quality-of-care audit system developed in 1995 to improve perinatal outcomes in SA.<sup>[9]</sup> Our analysis of PIIP data from 2008 to 2017 represents 80% of the 9 million births in SA over that 10-year period. Our objectives were to report the prevalence of stillbirths in WLWH, and explore differences in stillbirth rates based on maternal HIV serostatus and prophylactic v. combination ART.

## Methods

### Setting

SA national ART regimens for PMTCT have changed over time. Before 2010, single-dose nevirapine was given in labour. In 2010, dual ART, combining single-dose nevirapine and zidovudine, was introduced in labour. From 2011 to 2013, the PMTCT regimen included zidovudine from 14 weeks' gestation through delivery, and nevirapine, lamivudine and tenofovir in labour. In 2014, lifelong cART was rolled out for pregnant women, with fixed drug combinations of as first-line regimens. Currently, lifelong cART is recommended at the time of HIV diagnosis regardless of pregnancy status. We extracted ART usage in pregnant WLWH from the PIIP database. However, details on ART usage in neonates or in women after birth were unavailable.

### Analysis

Stillbirth was defined as a previously viable fetus born dead at 28 or more weeks of gestation, or a birth weight of at least 500 g. We used  $\chi^2$  tests to compare demographic characteristics and pregnancy outcomes by maternal HIV serostatus and between ART regimens. The PIIP received ethical approval from the University of Pretoria in 1995, and was subsequently adopted as a nationally approved programme. The National Perinatal Morbidity and Mortality Committee granted permission to carry out this secondary analysis.

## Results

Between January 2008 and December 2017, 7 454 172 deliveries were recorded in the PIIP database: 1 607 757 (22%) to WLWH, 4 321 619 (58%) to HIV-uninfected women and 1 524 796 (20%) to women with unknown HIV serostatus. Over this 10-year period, 150 682 stillbirths were recorded, which equates to a stillbirth rate (SBR) of 20/1 000 pregnancies. Among all women with a stillbirth, HIV testing increased from 68% in 2008 to 98% in 2017. Of the 150 682 stillbirths, 40 177 (26%, SBR= 25/1000) were delivered by WLWH, 94 305 (63%, SBR = 22/1 000) by HIV-uninfected women and 16 200 (11%, SBR = 11/1

000) by HIV-unknown women. The SBRs between these three groups were significantly different ( $p<0.001$ ).

Of the 40 177 WLWH who had stillbirths, 22 954 (57%) received some form of ART during pregnancy; the proportion of WLWH with a stillbirth receiving ART rose from 11% in 2008 to 86% in 2017. The SBR was highest among WLWH not on ART (SBR = 48/100). Among WLWH on some form of ART, the percentage of stillbirths was significantly higher in those taking lifelong cART than those taking prophylactic ART (2.3% v. 1.7%,  $p<0.001$ ).

## Discussion

In this study of stillbirths over a 10-year period in SA, SBRs were similar for WLWH and HIV-uninfected women. Women with untreated HIV had the highest SBRs. Our analysis demonstrates a marked increase in HIV testing and cART use over this decade, further highlighting the success of the PMTCT programme. However, among WLWH, those receiving cART had a higher SBR than those on prophylactic ART. This was a small but significant difference.

The primary strength of our study is the large sample size, which captured 80% of 9 million births over a 10-year period in SA. The limitations of the study include a high proportion (11%) of women with unknown HIV status among whom the SBR was low; the reason for this latter finding is unclear. Our study also had no data on duration or adherence to prescribed ART regimens, and unaccounted-for changes in pregnancy care might have affected SBRs over time.

In summary, the effects of HIV and ART on the fetus and placenta are poorly understood. Future studies should include surveillance of WLWH on cART for adverse fetal outcomes, including unexplained stillbirth, preterm birth, low birthweight and other effects of fetal inflammation which may be triggered by maternal HIV infection, cART use, or both.<sup>[10,11]</sup> Future analyses should also be stratified by timing of cART initiation (pre v. post conception), and specific cART regimen.

## Acknowledgements.

SM: SA Medical Research Council Midcareer Scientist Award.

## References

1. Blencowe H, Cousens S, Jassir F, et al. : National, regional and worldwide estimates of stillbirth rates in 2015, with trends from 2000: A systematic analysis. *Lancet Global Health* 2016;4:e98–108. 10.1016/S2214-109X(15)00275-2 [PubMed: 26795602]
2. Abuogi L, Humphrey J, Mpody C, et al. Achieving UNAIDS 90-90-90 targets for pregnant and postpartum women in sub-Saharan Africa: Progress, gaps and research needs. *J Virus Eradication* 2018;4(Suppl2):S33–S39.
3. UNAIDS. Miles to go closing gaps, breaking barriers, righting injustices. [http://www.unaids.org/sites/default/files/media\\_asset/miles-to-go\\_en.pdf](http://www.unaids.org/sites/default/files/media_asset/miles-to-go_en.pdf) (accessed 19 March 2020).
4. Avert. Prevention of mother to child transmission of HIV. <https://www.avert.org/professionals/hivprogramming/prevention/prevention-mother-child> (accessed 19 March 2020).

5. United Nations Children’s Fund. Connecting the dots. New York: UNICEF, 2020. [https://www.unicef.org/southafrica/SAF\\_resources\\_pmtctmores.pdf](https://www.unicef.org/southafrica/SAF_resources_pmtctmores.pdf) (accessed 19 March 2020).
6. Saleska J, Turner A, Maierhofer C, Clark J, Kwiek J. Use of antiretroviral therapy during pregnancy and adverse birth outcomes among women living with HIV-1 in low- and middle-income countries: A systematic review. *J Acquir Immune Defic Syndr* 2018;79:1–9. 10.1097/qai.0000000000001770 [PubMed: 29847475]
7. Xiao P, Zhou Y, Chen Y, et al. Association between maternal HIV infection and low birth weight and prematurity: A meta-analysis of cohort studies. *BMC Pregnancy Childbirth* 2015;15(1):246. 10.1186/s12884-015-0684-z [PubMed: 26450602]
8. Malaba T, Phillips T, Le Roux S, et al. Antiretroviral therapy use during pregnancy and adverse birth outcomes in South African women. *Int J Epidemiology* 2017;46(5):1578–1689.
9. Perinatal Problem Identification Program. <https://www.up.ac.za/centre-for-maternal-fetal-newborn-and-child-healthcare/article/2871749/the-perinatal-problem-identification-programme/> (accessed 20 August 2021).
10. Gotsch F, Romero R, Kusanovic P, et al. The fetal inflammatory response. *Clin Obstet Gynaecol* 2007;50(3):652–683. 10.1097/grf.0b013e31811ebef6
11. Cardenas I, Means R, Aldo P. Viral infection of the placenta leads to fetal inflammation and sensitization to bacterial products predisposing to preterm labor. *J Immunol* 2010;185(2):1248–1257. 10.4049/jimmunol.1000289 [PubMed: 20554966]